1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited

BXPHF
Botanix Pharmaceuticals LimitedUS flagOther OTC
0.01
USD
- -
- -
25.90MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.43
-0.03
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
- -
-0.01
-0.01
-0.01
-0.05
Free Cash Flow per Basic Share
-0.24
-0.03
-0.01
- -
-0.01
- -
- -
- -
- -
- -
-0.01
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.74
0.01
-0.01
0.02
0.01
0.03
- -
0.02
0.02
- -
0.01
0.06
0.03
Tangible Book Value per Share
-0.58
0.05
0.01
0.02
0.01
0.03
- -
0.03
0.02
- -
0.01
0.05
0.03
Basic Weighted Avg Shares
4
41
86
158
434
488
760
936
973
976
1,154
1,502
1,845
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
6
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-12,431.05
-2,568.82
-1,499.72
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
Net Income, GAAP
-2
-1
-1
-2
-5
-11
-17
-17
-3
-13
-9
-14
-86
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-8,893.05
-2,304.63
-1,500.65
Working Capital
-3
2
1
3
5
16
- -
23
21
7
12
79
75
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23
Total Equity
-3
2
1
3
5
16
1
24
21
8
23
109
81
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-117.01
-105.09
- -
- -
-18.01
-127.96
-90.3
-24.31
-117.83

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
453.24%
91.45%
-25.23%
Free Cash Flow
- -
7,059.13%
-94.17%
Net Income, GAAP
119.03%
151.78%
522.91%
Sales/Revenue/Turnover
- -
- -
856.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
6

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.05

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Howie McKibbon
Full Time Employees
11
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
41-47 Colin Street West Perth WA Australia 6005
IPO Date
Sep 9, 2019
Website
botanixpharma.com
Similar Companies
Bloomios, Inc. (BLMS)
NIHON CHOUZAI Co.,Ltd. (3341.T)
Bafna Pharmaceuticals Limited (BAFNAPH.NS)
Hindustan Bio Sciences Limited (HINDBIO.BO)
TSI Group Co Ltd (603262.SS)
Hanall Biopharma Co., Ltd. (009420.KS)
Business
Botanix Pharmaceuticals Limited (ASX:BOT; OTCQX:BXPHF) is an Australia-based clinical-stage dermatology company that develops and commercializes topical prescription treatments for serious skin diseases and infections using its proprietary Permetrex transdermal drug delivery technology and synthetic cannabidiol platform. The company offers Sofdra (sofpironium bromide) gel 12.45%, the first FDA-approved topical anticholinergic treatment for primary axillary hyperhidrosis in adults and children aged nine and older; BTX 1503 transdermal gel for moderate to severe acne, pending Phase 3 studies; BTX 1702 for papulopustular rosacea, with positive Phase 1b/2 results; BTX 1204A for atopic dermatitis, following successful canine proof-of-concept; and BTX 1801 antimicrobial gel targeting Staphylococcus aureus and MRSA, with completed Phase 2a and pending Phase 2b studies initially for hemodialysis patients. Founded in 1984 and headquartered in West Perth, Australia, with key operations in Philadelphia and Phoenix, USA, Botanix targets broad dermatology markets including acne, rosacea, dermatitis, hyperhidrosis, and antimicrobial applications primarily in the United States and Australia. In 2025, the company successfully launched Sofdra commercially in the US following FDA approval, achieving 50% quarter-over-quarter prescription growth to 20,418 units and US$7.1 million in net revenue in Q1 FY2026, while expanding its sales force from 27 to 50 representatives; it also presented Sofdra data at leading dermatology conferences and improved gross-to-net yields through its proprietary fulfillment platform.

Company News

APIChatGPT

  • seekingalpha.com

    Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Sofdra Update Transcript

  • seekingalpha.com

    Botanix Pharmaceuticals Limited (BXPHF) Q2 2026 Earnings Call Transcript